Profusa has signed a distribution agreement with MedSell to commercialize its Lumee Oxygen tissue monitoring device in France, expanding its existing footprint in Spain, Germany, the Benelux countries, Austria, the United Kingdom and Scandinavia. This network now covers approximately 200,000 annual critical limb ischemia (CLI) cases across the European Union. The partnership with MedSell complements Profusa’s collaboration with Dr. Yann Gouëffic at Groupe Hospitalier Paris Saint Joseph, who accounts for about 8% of all critical limb threatening ischemia (CLTI) cases in France and will adopt Lumee technology in clinical studies and home-monitoring initiatives. Profusa projects European revenues of $0.5–$2 million in 2026, rising to $9–$13 million in 2027, and aims to reach $200–$250 million by 2030 as it scales adoption in hospital and outpatient wound-care clinics.

In a balance-sheet recapitalization move, Profusa restructured its Senior Secured Convertible Notes to enhance repayment flexibility and minimize shareholder dilution. The conversion floor price was increased to $0.35 from $0.10, mandatory cash and equity amortization payments originally scheduled for early 2026 were eliminated, and final payment is now due at the 18-month maturity date. Additionally, mandatory equity line of credit (ELOC) payments were raised from 17.5% to 33% for shares issued under the existing registration statement and to 50% for shares issued under any new Form S-1 filing. Profusa’s CFO highlighted that these changes will preserve capital for commercial initiatives and inventory build in first-quarter 2026, while the CEO emphasized renewed focus on revenue growth and long-term shareholder value.